Professor Desmond Yip

MB BS, FRACP
Clinical Director, Senior Staff Specialist, Canberra Hospital
Professor, ANU School of Medicine and Psychology
ANU College of Health and Medicine

Professor Desmond Yip is the Clinical Director of Medical Oncology at The Canberra Hospital, Professor at the ANU Medical School and Adjunct Professor at the University of Canberra. He is a full time practicing medical oncologist. His main clinical and research interests are in the area of gastrointestinal oncology and developmental therapeutics of cancer drugs. He also has subspecialty interests in renal cell carcinoma and gastrointestinal stromal tumours. He is presently a member of the Cancer Institute NSW eviQ Medical Oncology Reference Committee, Executive Member of the Medical Oncology Group of Australia, Treasurer of the Private Cancer Physicians of Australia and former Chair of the Clinical Oncology Group of Australia Gastrointestinal Group. He is a member of the Australian Government Professional Services Review Panel. He an active member of the Australasian Gastrointestinal Trials Group serving as current Chair of the Grants Committee, member of study management committees and Study Chair of an international multicentre randomised collaborative trial in gastrointestinal stromal tumours. He has been involved in the publication of over 140 journal articles and invited book chapters. He has been involved with two iterations of a Cochrane Collaboration Systematic Review in pancreatic cancer and also on the working party to update the Cancer Council Australia Clinical Guidelines on colorectal cancer. Professor Yip has worked in collaboration with the John James Foundation, Australian Government Department of Foreign Affairs and Trade (DFAT)/ Royal Australasian College of Physicians (RACP) Pacific Islands Program and Doctors Assisting in South-Pacific Islands (DAISI) to help develop cancer services in the Solomon Islands through in-country multidisciplinary missions, mentoring, supply of equipment and facilitating staff training visits to Canberra. He is present Chair of the Clinical Oncology Society of Australia Global Oncology Group.

Specialisation

  • Medical Oncology
  • Dunn, J, McCuaig, R, Tan, A et al. 2022, 'Selective Targeting of Protein Kinase C (PKC)-θ Nuclear Translocation Reduces Mesenchymal Gene Signatures and Reinvigorates Dysfunctional CD8+ T Cells in Immunotherapy-Resistant and Metastatic Cancers', Cancers, vol. 14, no. 6.
  • Prasanna, T, Malik, L, McCuaig, R et al. 2022, 'A Phase 1 Proof of Concept Study Evaluating the Addition of an LSD1 Inhibitor to Nab-Paclitaxel in Advanced or Metastatic Breast Cancer (EPI-PRIMED)', Frontiers in Oncology, vol. 12, pp. 1-11.
  • Zaheer, A, Naumovski, N, Toohey, K et al. 2022, 'Prediction models for venous thromboembolism in ambulatory adults with pancreatic and gastro-oesophageal cancer: protocol for systematic review and meta-analysis', BMJ Open, vol. 12, no. 3, pp. 1-7.
  • Bae, S, Brnabic, A, Crowe, P et al. 2022, 'Managing patients with advanced soft tissue sarcoma: Evolving landscape from an Australian perspective', Asia-Pacific Journal of Clinical Oncology, pp. 1-9.
  • Foo, T, Goldstein, D, Segelov, E et al. 2022, 'The Management of Unresectable, Advanced Gastrointestinal Stromal Tumours', Targeted Oncology, vol. 17, pp. 95-110.
  • Min, S, Roohullah, A, Tognela, A et al. 2022, 'Patient demographics and management landscape of metastatic colorectal cancer in the third-line setting: Real-world data in an australian population', Asia-Pacific Journal of Clinical Oncology, vol. 18, no. 2, pp. e56-e63.
  • Jain, A, Chitturi, S, Peters, G et al. 2021, 'Atezolizumab and bevacizumab as first line therapy in advanced hepatocellular carcinoma: Practical considerations in routine clinical practice', World Journal of Hepatology, vol. 13, no. 9, pp. 1132-1142.
  • Yan, A, Samarawickrema, I, Naunton, M et al. 2021, 'Models for predicting venous thromboembolism in ambulatory patients with lung cancer: A systematic review protocol', BMJ Open, vol. 11, no. 12, pp. 1-5.
  • Yan, A, Samarawickrema, I, Naunton, M et al. 2021, 'Risk factors and prediction models for venous thromboembolism in ambulatory patients with lung cancer', Healthcare, vol. 9, no. 6.
  • Burbury, K, Wong, Z, Yip, D et al. 2021, 'Telehealth in cancer care: during and beyond the COVIDâ€?19 pandemic', Internal Medicine Journal, vol. 51, pp. 125-133.
  • Shah, M, Bodoky, G, Starodub, A et al. 2021, 'Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1)', Asia Pacific Journal of Clinical Oncology.
  • Ward, I, Mel, A, Soma, A et al. 2021, 'A collaborative approach to meeting oncology challenges in island communities in the Asia-Pacific region', Journal of Medical Imaging and Radiation Oncology, vol. 65, no. 4, pp. 418-423.
  • Jain, A, Yip, D & Gananadha, S 2021, 'Neoadjuvant chemotherapy in pancreatic cancer: still many unanswered questions (Letter to the editor)', JAMA Surgery.
  • Hashim, C, Taib, N, Yoon, H et al. 2021, 'Psychometric Assessment of the Malay Version of the 14-Item Resilience Scale (RS-14) in Women With Breast Cancer', Journal of Nursing Measurement.
  • Pumpa, K, Dalton, J, Mara, J et al. 2021, 'Identifying women at risk of weight gain after a breast cancer diagnosis: Results from a cohort of Australian women', Health Promotion Journal of Australia.
  • Carroll, C, Andrew, E, Malik, L et al. 2021, 'Simple and effective bacterial-based intratumoral cancer immunotherapy', Journal for ImmunoTherapy of Cancer, vol. 9, no. 9.
  • Kanjanapan, Y, Blinman, P, Underhill, C et al. 2021, 'Medical Oncology Group of Australia position statement: COVID-19 vaccination in patients with solid tumours', Internal Medicine Journal, vol. 51, no. 6, pp. 955-959.
  • Wilson, B, Pokorny, A, Perera, S et al. 2021, 'Australia and New Zealand’s responsibilities in improving oncology services in the Asia-Pacific: A call to action', Asia Pacific Journal of Clinical Oncology.
  • Tie, J, Cohen, J, Lo, S et al. 2020, 'Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies', International Journal of Cancer, vol. -, no. -, pp. -.
  • Kanjanapan, Y & Yip, D 2020, 'Considerations for cancer immunotherapy during the COVID-19 pandemic', Medical Journal of Australia, vol. 213, no. 9, pp. 390-392.e1.
  • Yip, D & Kanjanapan, Y 2020, 'Characteristics and risk factors for microbial infections during cancer immune checkpoint therapy', Cancer Medicine, vol. 9, no. 23, pp. 9027-9035.
  • Travers, A, Jalali, A, Begbie, S et al. 2020, 'Real-World Treatment and Outcomes of Metastatic Colorectal Cancer Patients With a Poor or Very Poor Performance Status', Clinical Colorectal Cancer, vol. -, no. -, pp. -.
  • Tu, W, McCuaig, R, Tan, A et al. 2020, 'Targeting Nuclear LSD1 to Reprogram Cancer Cells and Reinvigorate Exhausted T Cells via a Novel LSD1-EOMES Switch', Frontiers in Immunology, vol. 11, no. -, pp. 1-23.
  • Almonte, A, Rangarajan, H, Yip, D et al. 2020, 'How does the gut microbiome influence immune checkpoint blockade therapy?', Immunology and Cell Biology, vol. Online.
  • Segelov, E, Underhill, C, Prenen, H et al. 2020, 'Practical considerations for treating patients with cancer in the COVID-19 pandemic', American Journal of Clinical Oncology, vol. 16, no. 8, pp. 467-482.
  • Prasanna, T, Wong, R, Price, T et al. 2020, 'Metastasectomy and BRAF mutation; an analysis of survival outcome in metastatic colorectal cancer', Current Problems in Cancer.
  • Jain, A, Yip, D & Shorthouse, A 2020, 'Survival and Outcomes after Noncompletion of Treatment for Anal Cancer', JAMA Oncology, vol. -, no. -, pp. -.
  • Jain, A, Sjoquist, K & Yip, D 2020, 'ESMO localised colon cancer guidelines: �can we improve on our surveillance protocols?� ', Annals of Oncology, vol. 31, no. 12, pp. 1778-1779.
  • Jain, A & Yip, D 2020, 'GEP-NET: Knowledge gaps in the recent ESMO Guidelines', Annals of Oncology, vol. 31, no. 9, pp. 1260-1261.
  • Prasanna, T, Wu, F, Yip, D et al. 2019, 'Immune modulation via epigenetic targeting to overcome immune checkpoint inhibitor resistance', Journal of Immunotherapy, vol. 11, no. 15, pp. 1263-1266.
  • Wu, F, McCuaig, R, Sutton, C et al. 2019, 'Nuclear-Biased DUSP6 Expression is Associated with Cancer Spreading Including Brain Metastasis in Triple-Negative Breast Cancer', International Journal of Molecular Sciences, vol. 20, no. 12.
  • Parakh, S, Randhawa, M, Nguyen, B et al. 2019, 'Real-world efficacy and toxicity of combined nivolumab and ipilimumab in patients with metastatic melanoma', Asia-Pacific Journal of Clinical Oncology, vol. 15, no. 1, pp. 26-30.
  • Beatty, L, Kemp, E, Coll, J et al. 2019, 'Finding My Way: results of a multicentre RCT evaluating a web-based self-guided psychosocial intervention for newly diagnosed cancer survivors', Supportive Care in Cancer, vol. 27, no. 7, pp. 2533-2544.
  • Randhawa, M, Archer, C, Gaughran, G et al. 2019, 'Combined immune therapy grade IV dermatitis in metastatic melanoma', Asia-Pacific Journal of Clinical Oncology, vol. 15, no. 4, pp. 262-265.
  • Randhawa, M, Gaughran, G, Archer, C et al. 2019, 'Vedolizumab in combined immune checkpoint therapy-induced infliximab-refractory colitis in a patient with metastatic melanoma: A case report', World Journal of Clinical Oncology, vol. 10, no. 10, pp. 350-357.
  • Mendis , S, Beck, S, Lee, B et al. 2019, 'Right versus left sided metastatic colorectal cancer: Teasing out clinicopathologic drivers of disparity in survival', Asia Pacific Journal of Clinical Oncology, vol. 15, no. 3, pp. 136-143.
  • Tio, M, Rai, R, Ezeoke, O et al. 2018, 'Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection', European Journal of Cancer, vol. 104, no. -, pp. 137-144.
  • Pokorny, A, Chin, V, Nagrial, A et al 2018, 'Metastatic pancreatic ductal adenocarcinoma: diagnosis and treatment with a view to the future', Internal Medicine Journal, vol. 48, no. 6, pp. 637-644.
  • Prasanna, T, Karapetis, C, Roder, D et al. 2018, 'The survival outcome of patients with metastatic colorectal cancer based on the site of metastases and the impact of molecular markers and site of primary cancer on metastatic pattern', Acta Oncologica, vol. 57, no. 11, pp. 1438ââ¬â1444.
  • Prasanna, T, Wu, F, Khanna, K et al 2018, 'Optimizing poly (ADPâ€?ribose) polymerase inhibition through combined epigenetic and immunotherapy', Cancer Science, vol. 109, no. 11, pp. 3383-3392.
  • Prasanna, T, Briggs, G, Jain, S et al. 2018, 'Massive fatal pulmonary haemorrhage during bevacizumab treatment following microwave ablation therapy for oligometastatic lung metastasis from rectal cancer', Interactive Cardiovascular and Thoracic Surgery, vol. 26, no. 3, pp. 514-515.
  • Chin, V, Nagrial, A, Sjoquist, K et al. 2018, 'Chemotherapy and radiotherapy for advanced pancreatic cancer', Cochrane Database of Systematic Reviews (CDSR), vol. 20, no. 3, pp. 1-165pp.
  • Tie, J, Cohen, J, Wang, Y et al. 2018, 'Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study', Gut, vol. 68, no. 4, pp. 663-671.
  • Aw, L, Turner, N, Wong, H et al. 2018, 'How accurate are medical oncologists' impressions of management of metastatic colorectal cancer in Australia?', Asia-Pacific Journal of Clinical Oncology, vol. 14, no. 2, pp. 167-174pp.
  • Boulding, T, McCuaig, R, Tan, A et al 2018, 'LSD1 activation promotes inducible EMT programs and modulates the tumour microenvironment in breast cancer', Scientific Reports, vol. 8, no. 73, pp. -.
  • Toohey, K, Pumpa, K, McKune, A et al. 2018, 'Does low volume high-intensity interval training elicit superior benefits to continuous low to moderate-intensity training in cancer survivors?', World Journal of Clinical Oncology, vol. 9, no. 1, pp. 1-12pp.
  • Brennan, B, Hemmings, C, Clark, I et al 2017, 'Universal molecular screening does not effectively detect Lynch syndrome in clinical practice', Therapeutic Advances in Gastroenterology, vol. 10, no. 4, pp. 361-371.
  • Quek, R, Farid, M, Kanjanapan, Y et al. 2017, 'Prognostic significance of KIT exon 11 deletion mutation in intermediate-risk gastrointestinal stromal tumor', Asia-Pacific Journal of Clinical Oncology, vol. 13, no. 3, pp. 115-124pp.
  • Squire, T, Buchanan, G, Rangiah, D et al. 2017, 'Does chronomodulated radiotherapy improve pathological response in locally advanced rectal cancer?', Chronobiology International, vol. 34, no. 4, pp. 492-503pp.
  • Lee, B, Wong, H, Tacey, M et al. 2017, 'The impact of bevacizumab in metastatic colorectal cancer with an intact primary tumor: Results from a large prospective cohort study', Asia-Pacific Journal of Clinical Oncology, vol. 13, no. 4, pp. 314-321.
  • Diwakarla, C, Hannan, K, Hein, N et al. 2017, 'Advanced pancreatic ductal adenocarcinoma - Complexities of treatment and emerging therapeutic options', World Journal of Gastroenterology, vol. 23, no. 13, pp. 2276-2285pp.
  • Quek, R, Farid, M, Kanjanapan, Y et al. 2017, 'Prognostic significance of KIT exon 11 deletion mutation in intermediate-risk gastrointestinal stromal tumor', Asia-Pacific Journal of Clinical Oncology, vol. 13, no. 3, pp. 115-124pp.
  • Lee, M, Lok, S, Turner, N et al. 2017, 'A real-world registry to evaluate HER2-directed therapy in Australian patients with metastatic breast cancer', 53rd American Society of Clinical Oncology Annual Meeting, ed. Stephen A. Cannistra, American Society of Clinical Oncology, United States of America.
  • Tie, J, Cohen, J, Wang, Y et al. 2017, 'The potential of circulating tumor DNA (ctDNA) to guide adjuvant chemotherapy decision making in locally advanced rectal cancer (LARC)', 53rd American Society of Clinical Oncology Annual Meeting, ed. Stephen A. Cannistra, American Society of Clinical Oncology, United States of America.
  • Beatty, L, Kemp, E, Binnion, C et al. 2017, 'Uptake and adherence to an online intervention for cancer-related distress: older age is not a barrier to adherence but may be a barrier to uptake', Supportive Care in Cancer, vol. 25, no. 6, pp. 1905-1914.
  • Kuo, J, De Silva, M, Diwakarla, C et al. 2017, 'A Rapid Access Clinic to improve delivery of ambulatory care to cancer patients', Asia-Pacific Journal of Clinical Oncology, vol. 13, no. 3, pp. 179-184.
  • Bray, V, Dhillon, H, Bell, M et al. 2017, 'Evaluation of a Web-Based Cognitive Rehabilitation Program in Cancer Survivors Reporting Cognitive Symptoms After Chemotherapy', Journal of Clinical Oncology, vol. 35, no. 2, pp. 217-225.
  • Lok, S, Yip, D, Greenberg, S et al. 2017, 'Tumour Characteristics and Treatment Patterns in Relapsed Metastatic HER2 Positive Breast Cancer', Clinical Oncology Society of Australia (COSA) Annual Scientific Meeting (ASM) 2017, Wiley-Blackwell Publishing Ltd, United States of America, pp. 128-129.
  • Rai, R, Ezeoke, O, McQuade, J et al. 2017, 'Immunotherapy in patients with concurrent solid organ transplant, HIV, and Hepatitis B and C', Annals of Oncology, vol. 28, no. 5, pp. 1pp.
  • Wong, H, Lee, B, Field, K et al. 2016, 'Impact of Primary Tumor Site on Bevacizumab Efficacy in Metastatic Colorectal Cancer', Clinical Colorectal Cancer, vol. 15, no. 2, pp. e9-e15.
  • Lee, B, Wong, H, Tie, J et al. 2016, 'Impact of anti-VEGF therapy in metastatic colorectal cancer with an intact primary tumour', Journal of Clinical Oncology, vol. 34, no. Supplement 4, pp. Abstract Number: 650.
  • Toohey, K, Pumpa, K, Arnolda, L et al. 2016, 'A pilot study examining the effects of low-volume high-intensity interval training and continuous low to moderate intensity training on quality of life, functional capacity and cardiovascular risk factors in cancer survivors', PeerJ, vol. 4, no. 10, pp. 1-20pp.
  • Parakh, S, Gananadha, S, Allen, R et al. 2016, 'Cholecystitis after yttrium-90 resin microsphere radioembolization treatment: Clinical and pathologic findings', Asian Journal of Surgery, vol. 39, no. 3, pp. 144-148.
  • Boulding, T, Wu, F, McCuaig, R et al 2016, 'Differential roles for DUSP family members in epithelial-to-mesenchymal transition and cancer stem cell regulation in breast cancer', PLOS ONE (Public Library of Science), vol. 11, no. 2, pp. 1-23.
  • Garvey, G, Thewes, B, He, V et al 2016, 'Indigenous cancer patient and staff attitudes towards unmet needs screening using the SCNAT-IP', Supportive Care in Cancer, vol. 24, no. 1, pp. 215-223.
  • Day, D, Kanjanapan, Y, Kwan, E et al. 2016, 'Benefit from cytoreductive nephrectomy and the prognostic role of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma', Internal Medicine Journal, vol. 46, no. 11, pp. 1291-1297pp.
  • Malik, L, Chua, Y, BUTT, N et al. 2016, 'Single institutional series of neuroendocrine tumors managed in the Australian Capital Territory', Asia-Pacific Journal of Clinical Oncology, vol. 12, no. 1, pp. E133-E140.
  • Thewes, B, Davis, E, Girgis, A et al. 2016, 'Routine screening of Indigenous cancer patients' unmet support needs: a qualitative study of patient and clinician attitudes', International Journal for Equity in Health, vol. 15, no. 90, pp. 12pp.
  • Carlino, M, Kwan, V, Miller, D et al. 2015, 'New RAS-Mutant Pancreatic Adenocarcinoma With Combined BRAF and MEK Inhibition for Metastatic Melanoma', Journal of Clinical Oncology, vol. 33, no. 11, pp. e52-e56.
  • Kuo, J, Hawkins, C & Yip, D 2015, 'APPLICATION OF HYPERSENSITIVITY SKIN TESTING IN CHEMOTHERAPY INDUCED PNEUMONITIS', Asia Pacific Allergy, vol. 5, no. 4, pp. 234 - 236.
  • Nagrial, A, Chin, V, Sjoquist, K et al. 2015, 'Second-line treatment in inoperable pancreatic adenocarcinoma: A systematic review and synthesis of all clinical trials', Critical Reviews in Oncology/Hematology, vol. 96, no. 3, pp. 483-497.
  • Brulé, S, Jonker, D, Karapetis, C et al. 2015, 'Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17', European Journal of Cancer, vol. 51, no. 11, pp. 1405-1414.
  • Parakh, S, Wong, H, Rai, R et al. 2015, 'Patterns of care and outcomes for elderly patients with metastatic colorectal cancer in Australia', Journal of Geriatric Oncology, vol. 6, no. 5, pp. 387-394.
  • Beatty, L, Kemp, E, Wade, T et al. 2015, 'Finding My Way: Protocol of a randomised controlled trial evaluating an internet self-help program for cancer-related distress', BMC Cancer, vol. 15, no. 1, pp. 328-328.
  • Day, D, Kanjanapan, Y, Kwan, E et al. 2015, 'Patterns of care for metastatic renal cell carcinoma in Australia', BJU International, vol. 116, no. Issue Supplement S3, pp. 36-41.
  • Lakhanpal, R, Yoong, J, Joshi, S et al. 2015, 'Geriatric assessment of older patients with cancer in Australia-A multicentre audit', Journal of Geriatric Oncology, vol. 6, no. 3, pp. 185-193.
  • Lee, C, Goldstein, D, Gibbs, E et al 2015, 'Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib', European Journal of Cancer, vol. 51, no. 7, pp. 852-860.
  • Roohullah, A, Wong, H, Sjoquist, K et al. 2015, 'Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab', World Journal of Gastroenterology, vol. 21, no. 17, pp. 5352-5358.
  • Turner, N, Wong, H, Field, K et al. 2015, 'Novel quality indicators for metastatic colorectal cancer management identify significant variations in these measures across treatment centers in Australia', Asia-Pacific Journal of Clinical Oncology, vol. 11, no. 3, pp. 262-271.
  • Kanjanapan, Y, Prasanna, T, Perampalam, S et al. 2015, 'The challenge of managing adrenocortical carcinoma: two case studies', International Journal of Endocrine Oncology, vol. 2, no. 3, pp. 175 - 184.
  • Ransom, D, Wilson, K, Fournier, M et al. 2014, 'Final results of Australasian Gastrointestinal Trials Group ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines', Annals of Oncology, vol. 25, no. 1, pp. 117-121.
  • Hemmings, C & Yip, D 2014, 'The changing face of GIST: implications for pathologists', Pathology, vol. 46, no. 2, pp. 141-148.
  • Kuo, J, Tazbirkova, A, Allen, R et al 2014, 'Serious hepatic complications of selective internal radiation therapy with yttrium-90 microsphere radioembolization for unresectable liver tumors', Asia-Pacific Journal of Clinical Oncology, vol. 10, no. 3, pp. 266-272.
  • Yip, D, Zalcberg, J, Ackland, S et al 2014, 'Controversies in the management of gastrointestinal stromal tumors', Asia-Pacific Journal of Clinical Oncology, vol. 10, no. 3, pp. 216-227.
  • Kuo, J, Parakh, S & Yip, D 2014, 'Regorafenib-induced hyperammonemic encephalopathy', Journal of Clinical Pharmacy and Therapeutics, vol. 39, no. 4, pp. 446-448.
  • SOMMEIJER, D, Karapetis, C, Zalcberg, J et al. 2014, 'The relationship between rash, tumour KRAS mutation status and clinical and quality of life outcomes in patients with advanced colorectal cancer treated with cetuximab in the NCIC CTG/AGITG CO.17', Acta Oncologica, vol. 53, no. 7, pp. 877-884.
  • Sjoquist, K, Chin, V, Chantrill, L et al 2014, 'Personalising pancreas cancer treatment: When tissue is the issue', World Journal of Gastroenterology, vol. 20, no. 24, pp. 7849-7863.
  • Tejani, N, Cooper, A, Rezo, A et al 2014, 'Numb chin syndrome: A case series of a clinical syndrome associated with malignancy', Journal of Medical Imaging and Radiation Oncology, vol. 58, no. 6, pp. 700-705.
  • Malik, L, Kuo, J, Yip, D et al 2014, 'How well informed is the informed consent for cancer clinical trials?', Clinical Trials, vol. 11, no. 6, pp. 686-688.
  • Leong, D, Rai, R, Nguyen, B et al 2014, 'Advances in adjuvant systemic therapy for non-small-cell lung cancer', World Journal of Clinical Oncology, vol. 5, no. 4, pp. 633-645.
  • Kuo, J, Hawkins, C & Yip, D 2014, 'Treatment outcomes of rapid desensitisation protocols for chemotherapeutic agents and monoclonal antibodies following hypersensitivity reactions', Internal Medicine Journal, vol. 44, no. 5, pp. 442-449.
  • Field, K, Wong, H, Shapiro, J et al 2013, 'Developing a national database for metastatic colorectal cancer management: perspectives and challenges', Internal Medicine Journal, vol. 43, no. 11, pp. 1224-1231.
  • Malik, L, Hemmings, C, Beshay, V et al 2013, 'Metastatic gastrointestinal stromal tumour of the ileum with dual primary c-KIT missence mutations', Pathology, vol. 45, no. 6, pp. 604-606.
  • GRIMISON, P, PHILLIPS, F, Butow, P et al 2013, 'Are visiting oncologists enough? A qualitative study of the needs of Australian rural and regional cancer patients, carers and health professionals', Asia-Pacific Journal of Clinical Oncology, vol. 9, no. 3, pp. 226-238.
  • Webber, K, Cooper, A, Kleiven, H et al 2011, 'Management of metastatic renal cell carcinoma in the era of targeted therapies', Internal Medicine Journal, vol. 41, no. 8, pp. 594-605.
  • Kosmider, S, Tan, T, Yip, D et al 2011, 'Radioembolization in combination with systemic chemotherapy as first-line therapy for liver metastases from colorectal cancer', Journal of Vascular and Interventional Radiology, vol. 22, no. 6, pp. 780-786.
  • Zalcberg, J, Yip, D, Hemmings, C et al 2011, 'Gastrointestinal Stromal Tumors', in Charles Blanke, Claus Rodel, Mark Talamonti (ed.), Gastrointestinal Oncology: A Practical Guide, Springer, Berlin, Heidelberg Germany, pp. 139-172.
  • Tan, T, PRANAVAN, G, Haxihimolla, H et al 2010, 'New systemic treatment options for metastatic renal-cell carcinoma in the era of targeted therapies', Asia-Pacific Journal of Clinical Oncology, vol. 6, no. 1, pp. 5-18.
  • Yip, D & Gorddard, N 2009, 'Oncological Emergencies: Diagnosis and Management', in Monica Robotin (ed.), When Cancer Crosses Disciplines: A Clinician's Handbook, Imperial College Press, United Kingdom, pp. 201-230.
  • Tan, T, Hemmings, C, Stafford-Bell, M et al 2009, 'The successful management of two pregnancies with wild type metastatic gastrointestinal stromal tumors', Asia-Pacific Journal of Clinical Oncology, vol. 5, pp. 187-192.
  • Hemmings, C, Broomfield, A, Bean, E et al 2009, 'Immunohistochemical expression of EGFR in colorectal carcinoma correlates with high but not low level gene amplification, as demonstrated by CISH', Pathology, vol. 41, no. 4, pp. 356-360.
  • Zalcberg, J, Desai, J, Mann, B et al 2008, 'Consensus approaches to best practice management of gastrointestinal stromal tumors', Asia-Pacific Journal of Clinical Oncology, vol. 4, no. 4, pp. 188-198.
  • PRANAVAN, G, Goldstein, D & Yip, D 2008, 'Response of Carney's triad-related metastatic gastrointestinal stromal tumor to sunitinib', Asia-Pacific Journal of Clinical Oncology, vol. 4, pp. 170-174.
  • Kanthan, G, Jayamohan, J, Yip, D et al 2007, 'Management of metastatic carcinoma of the uveal tract: an evidence-based analysis', Clinical and Experimental Ophthalmology, vol. 35, pp. 553-565.
  • Yip, D, Karapetis, C, Strickland, A et al 2007, 'Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer', Cochrane Database of Systematic Reviews (CDSR), no. 3, pp. Art. No.: CD002093..
  • Yip, D, Tan, T & Stevenson, B 2006, 'Docetaxel induced nasal septal peforation', Internal Medicine Journal, vol. 36, no. 7, pp. 471-2.
  • Davis, A, Craft, P & Yip, D 2005, 'Australian patterns of practice survey in the adjuvant systemic treatment of early breast cancer', Asia-Pacific Journal of Clinical Oncology, vol. 1, pp. 25-33.
  • Lim, L, Gibbs, P, Yip, D et al 2005, 'A prospective evaluation of treatment with Selective Internal Radiation Therapy (SIR-spheres) in patients with unresectable liver metastases from colorectal cancer previously treated with 5-FU based chemotherapy', BMC Cancer, vol. 5, no. 132, pp. doi:10.1186.
  • Grimpen, F, Yip, D, McArthur, G et al 2005, 'Resistance to imatinib, low-grade FDG-avidity on PET, and acquired KIT exon 17 mutation in gastrointestinal stromal tumour', Lancet Oncology, The, vol. 6, pp. 724-727.
  • Clarke, S, Boyer, M, Millward, M et al 2005, 'A phase 1/11 study of pemetrexed and vinorelbine in patients with non-small cell lung cancer', Lung Cancer, vol. 49, pp. 401-412.
  • Lim, L, Gibbs, P, Yip, D et al 2005, 'A prospective study of treatment with selective internal radiation therapy spheres in patients with unresectable primary or secondary hepatic malignancies', Internal Medicine Journal, vol. 35, pp. 222-227.
  • Yip, D & Goldstein, D 2005, 'Adding irinotecan to first-line gemcitabine improves tumour response in advanced pancreatic cancer', Cancer Treatment Reviews, vol. 31, pp. 236-241.
  • Hughes, B, Yip, D, Chao, M et al 2004, 'Audit of postoperative chemoradiotherapy as adjuvant therapy for resected gastroesophageal adenocarcinoma: An Australian multicentre experience', Australian and New Zealand Journal of Surgery, vol. 74, pp. 951-956.
  • Yip, D, Allen, R, Ashton, C et al 2004, 'Radiation-Induced Ulceration of the stomach secondary to hepatic embolization with radioactive yttrium microsheres in the treatment of metastatic colon cancer', Journal of Gastroenterology and Hepatology, vol. 19, no. 3, pp. 347-349.
  • Hughes, B, Yip, D, Goldstein, D et al 2004, 'Cerebral relapse of metastatic gastrointestinal stromal tumor during treatment with imatinib mesylate: Case report', BMC Cancer, vol. 4, pp. 1-6.
  • Gibbs, P, Chao, M, Jones, I et al 2004, 'Evidence Supports Adjuvant Radiotherapy in selected Patients with Rectal Cancer', Australian and New Zealand Journal of Surgery, vol. 74, pp. 152-157.
  • Chua, Y, Steer, C & Yip, D 2004, 'Recent advances in management of small-cell lung cancer', Cancer Treatment Reviews, vol. 30, pp. 521-543.

Oncology